Ophthalmology practice agrees to pay more than $2.9 million to settle kickback allegationsMarch 24th 2023
The U.S. Attorney' Office Eastern District of Texas reported Kleiman Evangelista Eye Centers has agreed to pay $2,902,505 to resolve False Claims Act allegations that it offered and paid kickbacks to optometrists. In a statement, the practice said it settled the the civil action to avoid a protracted legal battle and remains committed to optimizing patient outcomes while continuing to work with its patients’ valued optometrists when patients choose to have their care co-managed.
COPHy 2023: Durability associated with multi-target therapies is superior to anti-VEGF mono-target therapy in AMDMarch 24th 2023
Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®
MedPAC: Physician payments should be linked to inflation-based indexMarch 16th 2023
To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.
Trends in corneal treatment include cutting-edge advancementsMarch 15th 2023
Kamran M. Riaz, MD, a clinical associate professor and director of Medical Student Research at the Dean A. McGee Institute at the University of Oklahoma, recently discussed with Ophthalmology Times some of the latest trends in cornea treatment.
Intergalactic Therapeutics announces positive preclinical results of Its platform in ABCA4 retinopathiesMarch 15th 2023
Data for IG-002 show for the first time that a single subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable expression of human ABCA4 protein.
Harrow announces transitional pass-through reimbursement status for chloroprocaine hydrochloride ophthalmic gel 3%March 13th 2023
According to the company, in a clinical trial of chloroprocaine hydrochloride ophthalmic gel in patients undergoing routine cataract surgery, patients treated with the gel did not require any supplemental treatment to complete the intended surgical procedure.
Researchers uncover therapeutic target to aid in glaucoma treatmentMarch 13th 2023
The researchers from Indiana University School of Medicine found neurons use mitochondria for a steady source of energy, and restoring mitochondrial homeostasis in the diseased neurons can protect the optic nerve cells from being damaged.